Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells
Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We...
Gespeichert in:
Veröffentlicht in: | Molecular cancer therapeutics 2013-03, Vol.12 (3), p.314-325 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 325 |
---|---|
container_issue | 3 |
container_start_page | 314 |
container_title | Molecular cancer therapeutics |
container_volume | 12 |
creator | Hasei, Joe Sasaki, Tsuyoshi Tazawa, Hiroshi Osaki, Shuhei Yamakawa, Yasuaki Kunisada, Toshiyuki Yoshida, Aki Hashimoto, Yuuri Onishi, Teppei Uno, Futoshi Kagawa, Shunsuke Urata, Yasuo Ozaki, Toshifumi Fujiwara, Toshiyoshi |
description | Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells. |
doi_str_mv | 10.1158/1535-7163.MCT-12-0869 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1316377993</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1316377993</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</originalsourceid><addsrcrecordid>eNo9kc1u3CAUhVGVqJmkfYRWLLNxwo_BeFlN0jbSRNlM1ugaX3dc2WYKeKp5hTx1cSbpBtDlnHvhO4R84eyGc2VuuZKqqLiWN4_rbcFFwYyuP5BVrpvCKF6evZ5PmgtyGeNvxripBf9ILoSUXNWVXpGXuxkGug_-V4BxxJY6HAbaIqQd3eflLxwj7ad2dvmuOdK9kjQFmCK41B8g9X6i_oDB-RFpwNjHBJNDmjz1k_PDMfWOQouTP_RhXlrR3TxCNsWEPsJihNeh8RM572CI-PltvyLP3--365_F5unHw_rbpnCKm1Qg06xkXadKLGWlQbSmaTlrm0bohhkuSs2c6bRyiMaB6MpWC1U5KbKrFFpeketT3_zrPzPGZMc-Li-ACf0cLZeZWFXVtcxSdZK64GMM2Nl96EcIR8uZXWKwC2K7ILY5BsuFXWLIvq9vI-YmQ_3veucu_wHnFYau</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1316377993</pqid></control><display><type>article</type><title>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hasei, Joe ; Sasaki, Tsuyoshi ; Tazawa, Hiroshi ; Osaki, Shuhei ; Yamakawa, Yasuaki ; Kunisada, Toshiyuki ; Yoshida, Aki ; Hashimoto, Yuuri ; Onishi, Teppei ; Uno, Futoshi ; Kagawa, Shunsuke ; Urata, Yasuo ; Ozaki, Toshifumi ; Fujiwara, Toshiyoshi</creator><creatorcontrib>Hasei, Joe ; Sasaki, Tsuyoshi ; Tazawa, Hiroshi ; Osaki, Shuhei ; Yamakawa, Yasuaki ; Kunisada, Toshiyuki ; Yoshida, Aki ; Hashimoto, Yuuri ; Onishi, Teppei ; Uno, Futoshi ; Kagawa, Shunsuke ; Urata, Yasuo ; Ozaki, Toshifumi ; Fujiwara, Toshiyoshi</creatorcontrib><description>Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.</description><identifier>ISSN: 1535-7163</identifier><identifier>EISSN: 1538-8514</identifier><identifier>DOI: 10.1158/1535-7163.MCT-12-0869</identifier><identifier>PMID: 23315976</identifier><language>eng</language><publisher>United States</publisher><subject>Adenoviridae ; Apoptosis - genetics ; Bone Neoplasms - pathology ; Bone Neoplasms - therapy ; Bone Neoplasms - virology ; Cell Cycle - genetics ; Humans ; Oncolytic Virotherapy ; Oncolytic Viruses - genetics ; Osteosarcoma - pathology ; Osteosarcoma - therapy ; Osteosarcoma - virology ; Transcriptional Activation - genetics ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>Molecular cancer therapeutics, 2013-03, Vol.12 (3), p.314-325</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</citedby><cites>FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23315976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasei, Joe</creatorcontrib><creatorcontrib>Sasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Tazawa, Hiroshi</creatorcontrib><creatorcontrib>Osaki, Shuhei</creatorcontrib><creatorcontrib>Yamakawa, Yasuaki</creatorcontrib><creatorcontrib>Kunisada, Toshiyuki</creatorcontrib><creatorcontrib>Yoshida, Aki</creatorcontrib><creatorcontrib>Hashimoto, Yuuri</creatorcontrib><creatorcontrib>Onishi, Teppei</creatorcontrib><creatorcontrib>Uno, Futoshi</creatorcontrib><creatorcontrib>Kagawa, Shunsuke</creatorcontrib><creatorcontrib>Urata, Yasuo</creatorcontrib><creatorcontrib>Ozaki, Toshifumi</creatorcontrib><creatorcontrib>Fujiwara, Toshiyoshi</creatorcontrib><title>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</title><title>Molecular cancer therapeutics</title><addtitle>Mol Cancer Ther</addtitle><description>Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.</description><subject>Adenoviridae</subject><subject>Apoptosis - genetics</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - therapy</subject><subject>Bone Neoplasms - virology</subject><subject>Cell Cycle - genetics</subject><subject>Humans</subject><subject>Oncolytic Virotherapy</subject><subject>Oncolytic Viruses - genetics</subject><subject>Osteosarcoma - pathology</subject><subject>Osteosarcoma - therapy</subject><subject>Osteosarcoma - virology</subject><subject>Transcriptional Activation - genetics</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1535-7163</issn><issn>1538-8514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kc1u3CAUhVGVqJmkfYRWLLNxwo_BeFlN0jbSRNlM1ugaX3dc2WYKeKp5hTx1cSbpBtDlnHvhO4R84eyGc2VuuZKqqLiWN4_rbcFFwYyuP5BVrpvCKF6evZ5PmgtyGeNvxripBf9ILoSUXNWVXpGXuxkGug_-V4BxxJY6HAbaIqQd3eflLxwj7ad2dvmuOdK9kjQFmCK41B8g9X6i_oDB-RFpwNjHBJNDmjz1k_PDMfWOQouTP_RhXlrR3TxCNsWEPsJihNeh8RM572CI-PltvyLP3--365_F5unHw_rbpnCKm1Qg06xkXadKLGWlQbSmaTlrm0bohhkuSs2c6bRyiMaB6MpWC1U5KbKrFFpeketT3_zrPzPGZMc-Li-ACf0cLZeZWFXVtcxSdZK64GMM2Nl96EcIR8uZXWKwC2K7ILY5BsuFXWLIvq9vI-YmQ_3veucu_wHnFYau</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>Hasei, Joe</creator><creator>Sasaki, Tsuyoshi</creator><creator>Tazawa, Hiroshi</creator><creator>Osaki, Shuhei</creator><creator>Yamakawa, Yasuaki</creator><creator>Kunisada, Toshiyuki</creator><creator>Yoshida, Aki</creator><creator>Hashimoto, Yuuri</creator><creator>Onishi, Teppei</creator><creator>Uno, Futoshi</creator><creator>Kagawa, Shunsuke</creator><creator>Urata, Yasuo</creator><creator>Ozaki, Toshifumi</creator><creator>Fujiwara, Toshiyoshi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201303</creationdate><title>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</title><author>Hasei, Joe ; Sasaki, Tsuyoshi ; Tazawa, Hiroshi ; Osaki, Shuhei ; Yamakawa, Yasuaki ; Kunisada, Toshiyuki ; Yoshida, Aki ; Hashimoto, Yuuri ; Onishi, Teppei ; Uno, Futoshi ; Kagawa, Shunsuke ; Urata, Yasuo ; Ozaki, Toshifumi ; Fujiwara, Toshiyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenoviridae</topic><topic>Apoptosis - genetics</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - therapy</topic><topic>Bone Neoplasms - virology</topic><topic>Cell Cycle - genetics</topic><topic>Humans</topic><topic>Oncolytic Virotherapy</topic><topic>Oncolytic Viruses - genetics</topic><topic>Osteosarcoma - pathology</topic><topic>Osteosarcoma - therapy</topic><topic>Osteosarcoma - virology</topic><topic>Transcriptional Activation - genetics</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hasei, Joe</creatorcontrib><creatorcontrib>Sasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Tazawa, Hiroshi</creatorcontrib><creatorcontrib>Osaki, Shuhei</creatorcontrib><creatorcontrib>Yamakawa, Yasuaki</creatorcontrib><creatorcontrib>Kunisada, Toshiyuki</creatorcontrib><creatorcontrib>Yoshida, Aki</creatorcontrib><creatorcontrib>Hashimoto, Yuuri</creatorcontrib><creatorcontrib>Onishi, Teppei</creatorcontrib><creatorcontrib>Uno, Futoshi</creatorcontrib><creatorcontrib>Kagawa, Shunsuke</creatorcontrib><creatorcontrib>Urata, Yasuo</creatorcontrib><creatorcontrib>Ozaki, Toshifumi</creatorcontrib><creatorcontrib>Fujiwara, Toshiyoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular cancer therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasei, Joe</au><au>Sasaki, Tsuyoshi</au><au>Tazawa, Hiroshi</au><au>Osaki, Shuhei</au><au>Yamakawa, Yasuaki</au><au>Kunisada, Toshiyuki</au><au>Yoshida, Aki</au><au>Hashimoto, Yuuri</au><au>Onishi, Teppei</au><au>Uno, Futoshi</au><au>Kagawa, Shunsuke</au><au>Urata, Yasuo</au><au>Ozaki, Toshifumi</au><au>Fujiwara, Toshiyoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</atitle><jtitle>Molecular cancer therapeutics</jtitle><addtitle>Mol Cancer Ther</addtitle><date>2013-03</date><risdate>2013</risdate><volume>12</volume><issue>3</issue><spage>314</spage><epage>325</epage><pages>314-325</pages><issn>1535-7163</issn><eissn>1538-8514</eissn><abstract>Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.</abstract><cop>United States</cop><pmid>23315976</pmid><doi>10.1158/1535-7163.MCT-12-0869</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1535-7163 |
ispartof | Molecular cancer therapeutics, 2013-03, Vol.12 (3), p.314-325 |
issn | 1535-7163 1538-8514 |
language | eng |
recordid | cdi_proquest_miscellaneous_1316377993 |
source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adenoviridae Apoptosis - genetics Bone Neoplasms - pathology Bone Neoplasms - therapy Bone Neoplasms - virology Cell Cycle - genetics Humans Oncolytic Virotherapy Oncolytic Viruses - genetics Osteosarcoma - pathology Osteosarcoma - therapy Osteosarcoma - virology Transcriptional Activation - genetics Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Xenograft Model Antitumor Assays |
title | Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T05%3A11%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20programmed%20cell%20death%20pathways%20induced%20by%20p53%20transactivation%20overcome%20resistance%20to%20oncolytic%20adenovirus%20in%20human%20osteosarcoma%20cells&rft.jtitle=Molecular%20cancer%20therapeutics&rft.au=Hasei,%20Joe&rft.date=2013-03&rft.volume=12&rft.issue=3&rft.spage=314&rft.epage=325&rft.pages=314-325&rft.issn=1535-7163&rft.eissn=1538-8514&rft_id=info:doi/10.1158/1535-7163.MCT-12-0869&rft_dat=%3Cproquest_cross%3E1316377993%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1316377993&rft_id=info:pmid/23315976&rfr_iscdi=true |